Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study.
Seyed Majid Mousavi MovahedHamed AkhavizadeganFatemeh DolatkhaniSamaneh AkbarpourSeyed Aria NejadghaderiMorvarid NajafiParmida Sadat PezeshkiAkram Khalili NoushabadiHoomaan GhasemiPublished in: PloS one (2023)
The presence of AKI among COVID-19 patients treated with antiviral agents is linked to increased severity and mortality. Therefore, it is imperative to explore preventive measures for AKI development in patients receiving antiviral therapy. Larger-scale randomized controlled trials may be warranted to provide a more comprehensive understanding of these associations.
Keyphrases
- acute kidney injury
- coronavirus disease
- cardiac surgery
- sars cov
- randomized controlled trial
- risk factors
- cardiovascular events
- respiratory syndrome coronavirus
- mesenchymal stem cells
- systematic review
- coronary artery disease
- cardiovascular disease
- metabolic syndrome
- cell therapy
- study protocol
- smoking cessation
- glycemic control